David Y. Liu's Insider Trades & SAST Disclosures
David Y. Liu's most recent trade in Protagonist Therapeutics Inc was a trade of 35,656 Stock Option (right to buy) done . Disclosure was reported to the exchange on Nov. 16, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David Y. Liu.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Protagonist Therapeutics Inc | David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 35,656 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 16 Nov 2022 | 35,656 | 132,259 (0%) | 0% | 1.2 | 41,361 | Common Stock |
| Protagonist Therapeutics Inc | David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 35,331 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 16 Nov 2022 | 35,331 | 167,590 (0%) | 0% | 4.2 | 148,744 | Common Stock |
| Protagonist Therapeutics Inc | David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.87 per share. | 16 Nov 2022 | 13,767 | 80,878 (0%) | 0% | 0.9 | 11,977 | Common Stock |
| Protagonist Therapeutics Inc | David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 13,767 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 9,726 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 16 Nov 2022 | 9,726 | 90,604 (0%) | 0% | 1.9 | 18,382 | Common Stock |
| Protagonist Therapeutics Inc | David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 5,999 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 16 Nov 2022 | 5,999 | 96,603 (0%) | 0% | 1.9 | 11,338 | Common Stock |
| Protagonist Therapeutics Inc | David Y. Liu | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.28 per share. | 28 Feb 2022 | 2,119 | 66,538 (0%) | 0% | 24.3 | 51,449 | Common Stock |
| Protagonist Therapeutics Inc | David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 10,000 | 68,657 (0%) | 0% | 0 | Common Stock | |
| Protagonist Therapeutics Inc | David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 47.56 per share. | 17 Aug 2021 | 14,779 | 58,254 (0%) | 0% | 47.6 | 702,889 | Common Stock |
| Protagonist Therapeutics Inc | David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 10,000 | 13,767 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.87 per share. | 17 Aug 2021 | 10,000 | 73,033 (0%) | 0% | 0.9 | 8,700 | Common Stock |
| Protagonist Therapeutics Inc | David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 10,000 | 62,427 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges